Stock TETRALOGIC PHARMACEUTICALS CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Tetralogic Pharmaceuticals Corp Nasdaq

Equities

US88165U1097

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MEDIVIR : YEAR-END REPORT JANUARY - DECEMBER 2020
AQ
Medivir : strengthens its business development possibilities through a renegotiated agreement with TetraLogic regarding birinapant
AQ
Medivir AB Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation
CI
TetraLogic Pharmaceuticals Corporation Appoints Alexandre Zyngier to Board of Directors and Management
CI
Tetralogic Pharmaceuticals Corporation Announces Management Resignations
CI
Medivir AB (OM:MVIR B) completed the acquisition of substantially all the assets of TetraLogic Pharmaceuticals Corporation.
CI
TetraLogic Pharmaceuticals Corporation(OTCPK:TLOG) dropped from S&P TMI Index
CI
TetraLogic Pharmaceuticals Corporation(OTCPK:TLOG) dropped from NASDAQ Composite Index
CI
Medivir AB (OM:MVIR B) entered into a definitive asset purchase agreement to acquire substantially all the assets of TetraLogic Pharmaceuticals Corporation for approximately $170 million.
CI
TetraLogic Pharmaceuticals Corporation Announces Resignation of Douglas Reed as M. D, Effective July 21, 2016
CI
TetraLogic Pharmaceuticals Corporation Announces Executive Changes
CI
TetraLogic Pharmaceuticals Corporation(NasdaqGM:TLOG) dropped from CRSP US Total Market Index
CI
TetraLogic Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt
CI
TetraLogic Pharmaceuticals Corporation Announces Resignation of Douglas E. Onsi as Member of Board of Directors, Effective February 5, 2016
CI
TetraLogic Pharmaceuticals Corporation Announces Management Terminations; Authorizes the Implementation of a 19 Person Reduction in Staff
CI
TetraLogic Pharmaceuticals Corporation Announces Results of the Interim Analyses of Two Clinical Studies
CI
TetraLogic Pharmaceuticals Corporation Announces Resignation of Michael Steinmetz from the Board of Directors, Effective December 15, 2015
CI
TetraLogic Pharmaceuticals Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides Update on SHAPE Alopecia Areata Program
CI
TetraLogic Pharmaceuticals Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
CI
Certain shares of TetraLogic Pharmaceuticals Corporation's Common Stock are subject to a Lock-Up Agreement Ending on 30-JUL-2015.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLOG Stock
  4. Stock
  5. News Tetralogic Pharmaceuticals Corp